> top > docs > PubMed:21935747 > annotations

PubMed:21935747 JSONTXT

Annnotations TAB JSON ListView MergeView

c_corpus

Id Subject Object Predicate Lexical cue
T1 21-30 PR:000000230 denotes precursor
T2 21-30 PR:000000291 denotes precursor
T3 31-38 CHEBI:34922 denotes pathway
T4 42-48 UBERON:0000310 denotes breast
T5 42-55 D001943 denotes breast cancer
T6 42-55 D001943 denotes breast cancer
T7 94-100 UBERON:0000310 denotes breast
T8 101-114 D063646 denotes tumorigenesis
T9 101-114 D063646 denotes tumorigenesis
T10 170-175 D009369 denotes tumor
T11 170-175 D009369 denotes tumor
T14 305-330 D000071960 denotes lobular carcinoma in situ
T15 305-330 D000071960 denotes lobular carcinoma in situ
T22 342-366 D002285 denotes ductal carcinoma in situ
T23 342-366 D002285 denotes ductal carcinoma in situ
T29 368-372 CVCL_5552 denotes DCIS
T28 368-372 D002285 denotes DCIS
T30 368-372 D002285 denotes DCIS
T31 420-426 UBERON:0000310 denotes breast
T32 427-434 D009369 denotes cancers
T33 427-434 D009369 denotes cancers
T35 562-566 CVCL_5552 denotes DCIS
T34 562-566 D002285 denotes DCIS
T36 562-566 D002285 denotes DCIS
T37 625-632 D009369 denotes cancers
T38 625-632 D009369 denotes cancers
T39 651-657 UBERON:0000479 denotes tissue
T40 686-689 CVCL_1K15 denotes HER
T41 686-690 PR:P04626 denotes HER2
T42 686-690 PR:000002082 denotes HER2
T43 686-690 PR:Q03557 denotes HER2
T44 686-690 PR:P34708 denotes HER2
T45 686-690 PR:Q5AK64 denotes HER2
T47 931-935 CVCL_5552 denotes DCIS
T46 931-935 D002285 denotes DCIS
T48 931-935 D002285 denotes DCIS
T50 1112-1116 CVCL_5552 denotes DCIS
T49 1112-1116 D002285 denotes DCIS
T51 1112-1116 D002285 denotes DCIS
T53 1155-1159 CVCL_5552 denotes DCIS
T52 1155-1159 D002285 denotes DCIS
T54 1155-1159 D002285 denotes DCIS
T56 1297-1301 CVCL_5552 denotes DCIS
T55 1297-1301 D002285 denotes DCIS
T57 1297-1301 D002285 denotes DCIS
T59 1429-1433 CVCL_5552 denotes DCIS
T58 1429-1433 D002285 denotes DCIS
T60 1429-1433 D002285 denotes DCIS
T61 1486-1495 PR:000000230 denotes precursor
T62 1486-1495 PR:000000291 denotes precursor
T63 1496-1503 CHEBI:34922 denotes pathway
T65 1533-1537 CVCL_5552 denotes DCIS
T64 1533-1537 D002285 denotes DCIS
T66 1533-1537 D002285 denotes DCIS
T67 1549-1552 CVCL_1K15 denotes HER
T68 1549-1553 PR:P04626 denotes HER2
T69 1549-1553 PR:000002082 denotes HER2
T70 1549-1553 PR:Q03557 denotes HER2
T71 1549-1553 PR:P34708 denotes HER2
T72 1549-1553 PR:Q5AK64 denotes HER2
T73 1750-1756 UBERON:0000310 denotes breast
T74 1757-1770 D063646 denotes tumorigenesis
T75 1757-1770 D063646 denotes tumorigenesis

PubmedHPO

Id Subject Object Predicate Lexical cue
T1 170-175 HP_0002664 denotes tumor
T2 420-434 HP_0003002 denotes breast cancers
T3 420-434 HP_0100013 denotes breast cancers
T4 427-434 HP_0002664 denotes cancers

Allie

Id Subject Object Predicate Lexical cue
SS1_21935747_3_0 305-330 expanded denotes lobular carcinoma in situ
SS2_21935747_3_0 332-336 abbr denotes LCIS
SS1_21935747_3_1 342-366 expanded denotes ductal carcinoma in situ
SS2_21935747_3_1 368-372 abbr denotes DCIS
SS1_21935747_8_0 849-871 expanded denotes invasive ductal cancer
SS2_21935747_8_0 873-876 abbr denotes IDC
SS1_21935747_8_1 940-949 expanded denotes low-grade
SS2_21935747_8_1 951-953 abbr denotes LG
SS1_21935747_8_2 959-969 expanded denotes high-grade
SS2_21935747_8_2 971-973 abbr denotes HG
AE1_21935747_3_0 SS1_21935747_3_0 SS2_21935747_3_0 abbreviatedTo lobular carcinoma in situ,LCIS
AE1_21935747_3_1 SS1_21935747_3_1 SS2_21935747_3_1 abbreviatedTo ductal carcinoma in situ,DCIS
AE1_21935747_8_0 SS1_21935747_8_0 SS2_21935747_8_0 abbreviatedTo invasive ductal cancer,IDC
AE1_21935747_8_1 SS1_21935747_8_1 SS2_21935747_8_1 abbreviatedTo low-grade,LG
AE1_21935747_8_2 SS1_21935747_8_2 SS2_21935747_8_2 abbreviatedTo high-grade,HG

UseCases_ArguminSci_Discourse

Id Subject Object Predicate Lexical cue
T1 0-56 DRI_Unspecified denotes Is there a low-grade precursor pathway in breast cancer?
T2 65-197 DRI_Background denotes ND: Newly proposed models of breast tumorigenesis suggest that low- and high-grade lesions have distinct tumor progression pathways.
T3 198-435 DRI_Background denotes Our objective was to examine the relationship between histologic grade and molecular subtype in women with lobular carcinoma in situ (LCIS) and ductal carcinoma in situ (DCIS) who developed subsequent ipsilateral invasive breast cancers.
T4 445-679 DRI_Background denotes Patients who underwent surveillance for classical LCIS (1994-2007) and those followed after lumpectomy±radiation for DCIS (1991-2004) who developed subsequent ipsilateral invasive cancers and had available tissue blocks were included.
T5 680-734 DRI_Background denotes ER/PR/HER2 surrogates were used for molecular subtype.
T6 744-1006 DRI_Background denotes Material was available for 27 patients with classical LCIS who developed ipsilateral invasive cancer (12 invasive ductal cancer [IDC], 14 invasive lobular, 1 mixed), and 26 patients with DCIS (12 low-grade [LG], 14 high-grade [HG]) who developed ipsilateral IDC.
T7 1007-1117 DRI_Background denotes No difference in age at diagnosis or median time to invasive cancer existed between groups with LCIS and DCIS.
T8 1118-1264 DRI_Background denotes When stratified by grade, 0 of 12 LG-DCIS developed LG-IDC (3 grade II; 9 grade III), and only 1 of 12 LCIS patients who developed IDC had LG-IDC.
T9 1265-1319 DRI_Unspecified denotes Thirteen (93%) patients with HG-DCIS developed HG-IDC.
T10 1320-1434 DRI_Background denotes In contrast, molecular subtype was maintained in 23 of 27 (85%) cases of LCIS and in 18 of 26 (69%) cases of DCIS.
T11 1448-1538 DRI_Background denotes These data do not support a low-grade precursor pathway characterized by LCIS and LG-DCIS.
T12 1539-1641 DRI_Background denotes ER/PR and HER2 status have a high rate of concordance between in situ and subsequent invasive lesions.
T13 1642-1771 DRI_Background denotes Additional studies of metachronous in situ and invasive lesions are needed to better understand pathways of breast tumorigenesis.

PubMed_Structured_Abstracts

Id Subject Object Predicate Lexical cue
T1 69-435 BACKGROUND denotes Newly proposed models of breast tumorigenesis suggest that low- and high-grade lesions have distinct tumor progression pathways. Our objective was to examine the relationship between histologic grade and molecular subtype in women with lobular carcinoma in situ (LCIS) and ductal carcinoma in situ (DCIS) who developed subsequent ipsilateral invasive breast cancers.
T2 445-734 METHODS denotes Patients who underwent surveillance for classical LCIS (1994-2007) and those followed after lumpectomy±radiation for DCIS (1991-2004) who developed subsequent ipsilateral invasive cancers and had available tissue blocks were included. ER/PR/HER2 surrogates were used for molecular subtype.
T3 744-1434 RESULTS denotes Material was available for 27 patients with classical LCIS who developed ipsilateral invasive cancer (12 invasive ductal cancer [IDC], 14 invasive lobular, 1 mixed), and 26 patients with DCIS (12 low-grade [LG], 14 high-grade [HG]) who developed ipsilateral IDC. No difference in age at diagnosis or median time to invasive cancer existed between groups with LCIS and DCIS. When stratified by grade, 0 of 12 LG-DCIS developed LG-IDC (3 grade II; 9 grade III), and only 1 of 12 LCIS patients who developed IDC had LG-IDC. Thirteen (93%) patients with HG-DCIS developed HG-IDC. In contrast, molecular subtype was maintained in 23 of 27 (85%) cases of LCIS and in 18 of 26 (69%) cases of DCIS.
T4 1448-1771 CONCLUSIONS denotes These data do not support a low-grade precursor pathway characterized by LCIS and LG-DCIS. ER/PR and HER2 status have a high rate of concordance between in situ and subsequent invasive lesions. Additional studies of metachronous in situ and invasive lesions are needed to better understand pathways of breast tumorigenesis.